Bright Minds reports positive preclinical data for BMB-201
NEW YORK - Bright Minds Biosciences Inc., a biotechnology company specializing in CNS disorder treatments, has announced positive preclinical results for its drug candidate BMB-201. The substance, designed to treat chronic pain, showed similar efficacy to morphine in pain models without the associated risks of dependency and side effects.
In the recent preclinical testing conducted under the National Institute of Health pain screening program, BMB-201 demonstrated its potential as a safer alternative to opioids. The study involved plantar incision and L5/L6 nerve ligation rat models, with BMB-201 being tested alongside morphine and gabapentin. Results indicated that BMB-201 was effective in reducing mechanical allodynia and pain-related behaviors, especially in female rodents at higher doses.
Jan Torleif Pedersen, Chief Scientific Officer of Bright Minds, highlighted the significance of these findings, stating that BMB-201's performance in preclinical models underscores the potential of serotonergic therapies in pain management. The company is now preparing to advance BMB-201 into clinical trials to further assess its safety and efficacy in human subjects.
BMB-201 is a selective 5-HT2A/2C receptor agonist, part of Bright Minds' portfolio targeting neurological and psychiatric disorders. The drug is a prodrug of BMB-A39a and has been engineered to minimize activity at the 5-HT2B receptor, potentially reducing the risk of side effects.
The promising preclinical results for BMB-201 were presented at the Society for Neuroscience's annual meeting at the NIH Satellite Forum, with the poster available on the company's website.
